Calcipotriol

Generic Name: Calcipotriol

Brand Names: Calcitrene, Dovobet, Dovonex, Enstilar, Sorilux, Taclonex, Wynzora

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₀O_₃

CAS Number: 112965-21-6

Unique Ingredient Identifier: 143NQ3779B

Background: Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.

Indication: For the treatment of moderate plaque psoriasis in adults.

Associated Conditions: Plaque psoriasis of the scalp, Psoriasis Vulgaris (Plaque Psoriasis)

Associated Therapies: -

Clinical Trials

Efficacy of Topical 5-Fluorouracil Vs Calcipotriol As Photodynamic Therapy Pre-treatment for Field Actinic Keratoses

Not Applicable

Not yet recruiting

Conditions: Actinic Keratosis of Face and Scalp
Actinic Keratoses

Interventions: Drug: 5-FU (fluorouracil)
Drug: Calcipotriol

First Posted Date: 2024-11-12

Last Posted Date: 2024-11-12

Lead Sponsor: St Vincent's University Hospital, Ireland

Target Recruit Count: 50

Registration Number: NCT06685588

Combination of Sotyktu and Enstilar for Plaque Psoriasis

Phase 4

Completed

Conditions: Psoriasis

Interventions: Drug: Enstilar
Drug: Deucravacitinib

First Posted Date: 2024-03-25

Last Posted Date: 2024-03-25

Lead Sponsor: Psoriasis Treatment Center of Central New Jersey

Target Recruit Count: 30

Registration Number: NCT06329258

Locations: 🇺🇸
Schweiger Derm Group, East Windsor, New Jersey, United States

Evaluation of the Effect of Topical Calcipotriol Versus Platelet-Rich Plasma

Not Applicable

Completed

Conditions: Alopecia Areata

Interventions: Drug: Calcipotriol

First Posted Date: 2023-07-20

Last Posted Date: 2023-10-19

Lead Sponsor: Egymedicalpedia

Target Recruit Count: 80

Registration Number: NCT05954104

Locations: 🇪🇬
Faculty of Dentistary - Aswan University, Aswan, Egypt

Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients

Phase 2

Recruiting

Conditions: Actinic Keratosis

Interventions: Procedure: Biopsy
Drug: Calcipotriene
Drug: Fluorouracil

First Posted Date: 2023-01-26

Last Posted Date: 2024-12-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 56

Registration Number: NCT05699603

Locations: 🇺🇸
University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 1 locations

Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)

Early Phase 1

Withdrawn

Conditions: Central Centrifugal Cicatricial Alopecia

Interventions: Drug: Calcipotriol
Drug: Subject's already prescribed drug

First Posted Date: 2022-06-13

Last Posted Date: 2023-08-31

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT05416320

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study

Phase 4

Active, not recruiting

Conditions: Psoriasis Vulgaris
Psoriasis
Skin Diseases
Skin Diseases, Papulosquamous
Skin and Connective Tissue Diseases

Interventions: Drug: Placebo-vehicle
Drug: Enstilar

First Posted Date: 2022-01-11

Last Posted Date: 2024-01-29

Lead Sponsor: Aarhus University Hospital

Target Recruit Count: 12

Registration Number: NCT05185258

Locations: 🇩🇰
Department of Dermatology, Aarhus N, Region Midtjylland, Denmark

Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails

Phase 2

Completed

Conditions: Nail Psoriasis

Interventions: Drug: Enstilar
Device: Ablative fractional laser

First Posted Date: 2020-10-08

Last Posted Date: 2022-03-02

Lead Sponsor: Bispebjerg Hospital

Target Recruit Count: 11

Registration Number: NCT04580537

Locations: 🇩🇰
Bispebjerg Hospital, Copenhagen, Capital Region, Denmark

Taltz in Combination With Enstilar for Psoriasis

Phase 4

Recruiting

Conditions: Psoriasis

Interventions: Drug: Enstilar

First Posted Date: 2020-05-04

Last Posted Date: 2020-05-04

Lead Sponsor: Psoriasis Treatment Center of Central New Jersey

Target Recruit Count: 25

Registration Number: NCT04372277

Locations: 🇺🇸
Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States

Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: HAT1
Drug: Calcipotriol

First Posted Date: 2019-02-21

Last Posted Date: 2019-02-21

Lead Sponsor: Haus Bioceuticals

Target Recruit Count: 174

Registration Number: NCT03848806

The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients

Phase 4

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Enstilar

First Posted Date: 2019-02-21

Last Posted Date: 2020-08-26

Lead Sponsor: Derm Research, PLLC

Target Recruit Count: 20

Registration Number: NCT03848871

Locations: 🇺🇸
DermResearch, PLLC, Louisville, Kentucky, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy